Biogen's Leqembi Real-World Data Shows Treatment Persistence, but Growth and Safety Hurdles Persist

What happened

Biogen presented real-world data at the AD/PD 2026 conference indicating that patients on LEQEMBI are choosing to stay on long-term treatment, which the company highlights as a positive sign for drug adherence and commercial potential. This data addresses some concerns about patient retention in the competitive Alzheimer's market, where LEQEMBI is the leading anti-amyloid therapy by prescriptions. However, the DeepValue report underscores that Biogen's overall revenue growth remains constrained by structural decline in multiple sclerosis and ongoing safety monitoring requirements for Alzheimer's treatments, such as MRI capacity limits. LEQEMBI's contribution, while growing, is still too small to fully offset MS erosion, with the report noting that launch products need to sustain ≥25% year-over-year growth to drive meaningful top-line improvement. Thus, while this persistence data is encouraging, it does not resolve the broader execution challenges in Biogen's transition from a declining MS base to a higher-risk growth portfolio.

Implication

The persistence data supports Leqembi's viability as a long-term treatment, potentially enhancing patient retention and steady revenue streams, which is crucial for Biogen's Alzheimer's strategy. However, as per the DeepValue report, Biogen's revenue stabilization hinges on offsetting MS decline with multiple launch products like Skyclarys and Qalsody, not just Leqembi, and safety oversight remains a bottleneck. Investors must recognize that repeated EPS guidance cuts from business-development charges and infrastructure constraints could dampen near-term earnings, limiting upside despite this positive data. Upcoming 2026 guidance and quarterly results will be critical to assess whether rare-disease growth and Leqembi adoption can collectively drive the ≥3% revenue growth needed for a valuation re-rating. Therefore, while the data reduces some adherence risks, it reinforces the need for patience and a wait-and-see approach, as the stock's current valuation at ~16.8x EPS already prices in much of the anticipated stabilization.

Thesis delta

The real-world persistence data for Leqembi slightly bolsters the bull case by mitigating adherence concerns, but it does not shift the core investment thesis. The thesis remains that Biogen must demonstrate sustained revenue growth from its launch portfolio to escape a flat revenue profile, and this news alone is insufficient to upgrade the 'WAIT' rating or alter the probability-weighted scenarios. Investors should continue to focus on 2026 guidance and quarterly metrics for signs of rare-disease growth acceleration or Leqembi scaling beyond current infrastructure limits.